IB
NBIX icon

Intrust Bank’s Neurocrine Biosciences NBIX Stock Holding History

Intrust Bank’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$337K Sell
1,999
-30
-1% -$4.45K 0.02% 336
2026
Q1 		$267K Sell
2,029
-229
-10% -$30.4K 0.02% 369
2025
Q4 		$320K Sell
2,258
-41
-2% -$5.94K 0.03% 324
2025
Q3 		$323K Hold
2,299
– – 0.03% 324
2025
Q2 		$289K Sell
2,299
-329
-13% -$37.7K 0.03% 347
2025
Q1 		$291K Sell
2,628
-106
-4% -$13.4K 0.03% 326
2024
Q4 		$373K Sell
2,734
-92
-3% -$11.4K 0.04% 292
2024
Q3 		$326K Sell
2,826
-28
-1% -$3.84K 0.03% 321
2024
Q2 		$393K Sell
2,854
-74
-3% -$10.1K 0.04% 281
2024
Q1 		$404K Sell
2,928
-49
-2% -$6.69K 0.04% 279
2023
Q4 		$392K Sell
2,977
-686
-19% -$79K 0.05% 286
2023
Q3 		$412K Sell
3,663
-1,270
-26% -$134K 0.05% 265
2023
Q2 		$465K Sell
4,933
-362
-7% -$35.4K 0.06% 253
2023
Q1 		$536K Sell
5,295
-486
-8% -$50.6K 0.07% 228
2022
Q4 		$690K Buy
5,781
+299
+5% +$35K 0.1% 187
2022
Q3 		$582K Buy
5,482
+519
+10% +$52.7K 0.09% 196
2022
Q2 		$484K Sell
4,963
-1,277
-20% -$118K 0.07% 234
2022
Q1 		$585K Buy
6,240
+3,355
+116% +$284K 0.07% 222
2021
Q4 		$246K Sell
2,885
-973
-25% -$89.5K 0.03% 358
2021
Q3 		$370K Buy
3,858
+400
+12% +$37.8K 0.05% 279
2021
Q2 		$336K Buy
3,458
+1,291
+60% +$124K 0.05% 287
2021
Q1 		$211K Buy
+2,167
New +$227K 0.03% 360

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Intrust Bank's NBIX Position: Q2 2026 in Review

Intrust Bank reduced its Neurocrine Biosciences (NBIX) stake by 1.5% in Q2 2026, selling an estimated $4.45K and leaving 1,999 shares worth $337K. The position accounts for 0.02% of the portfolio, ranked #336.

Intrust Bank first reported a position in NBIX in Q1 2021 and has held it in 22 quarters since. The position peaked at $690K in Q4 2022. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Intrust Bank held 1,999 shares of Neurocrine Biosciences worth $337K as of Q2 2026.
  • Intrust Bank sold 30 Neurocrine Biosciences shares in Q2 2026, an estimated $4.45K.
  • Neurocrine Biosciences made up 0.02% of Intrust Bank's portfolio in Q2 2026, its #336 holding.
  • Intrust Bank first reported a position in Neurocrine Biosciences in Q1 2021 and has held it in 22 quarters since.
  • Intrust Bank's Neurocrine Biosciences position peaked at $690K in Q4 2022.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Intrust Bank's 13F filing for Q2 2026, filed 5 Aug 2026.